Disease-modifier Drugs in Patients with Advanced Heart Failure: How to Optimize Their Use?

Massimo Iacoviello, Enrica Vitale, Maria Delia Corbo, Michele Correale, Natale Daniele Brunetti

Journal: Heart failure clinics 2021;17(4):561-573

PMID: 34511205

Full Text on Elsevier Science View on PubMed

Abstract

Therapy based on disease-modifier drugs is among the required criteria to diagnose advanced heart failure (AdvHF). Nevertheless, several conditions, such as hospitalization, hypotension, renal dysfunction, electrolyte abnormalities, medical inertia, and patients' adherence, can make the maintenance of optimal medical therapy in patients with AdvHF challenging. Moreover, in recent years, new classes of drugs able have been shown to be able to further modify the natural history of heart failure with reduced ejection fraction, but they are still not widely adopted. This article discusses the optimal use of disease-modifier drugs in patients with AdvHF as well as the possible usefulness of the new therapeutic opportunities.

Address: Cardiology Unit, Department of Medical and Surgical Sciences, University of Foggia, Viale Luigi Pinto 1, Foggia, Italy. Electronic address: [email protected].; Cardiology Unit, Department of Medical and Surgical Sciences, University of Foggia, Viale Luigi Pinto 1, Foggia, Italy.

DOI: 10.1016/j.hfc.2021.05.002

Link outs

Free resources

Medical:

https://medlineplus.gov/heartfailure.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Heart Failure, Hospitalization, Humans, Pharmaceutical Preparations, Stroke Volume, Ventricular Dysfunction, Left